Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 3
2015 3
2016 1
2017 2
2018 1
2019 1
2020 4
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hjelm eriksson m[au] (4 results)?
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Oudard S, et al. Among authors: hjalm eriksson m. J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28. J Clin Oncol. 2017. PMID: 28753384 Clinical Trial.
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C, Kellokumpu-Lehtinen PL; Investigators of the Scandinavian Prostate Cancer Group Study No 13. Lehtonen M, et al. Among authors: hjalm eriksson m. Anticancer Res. 2022 Jan;42(1):87-92. doi: 10.21873/anticanres.15460. Anticancer Res. 2022. PMID: 34969712 Clinical Trial.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13. Kellokumpu-Lehtinen PL, et al. Among authors: hjalm eriksson m. Eur Urol. 2019 Dec;76(6):823-830. doi: 10.1016/j.eururo.2019.08.010. Epub 2019 Aug 20. Eur Urol. 2019. PMID: 31443961 Clinical Trial.
An expression signature at diagnosis to estimate prostate cancer patients' overall survival.
Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjälm-Eriksson M, Harmenberg U, Cedermark GC, Andersson K, Ahrlund-Richter L, Pramana S, Pawitan Y, Nistér M, Nilsson S, Li C. Peng Z, et al. Among authors: hjalm eriksson m. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):81-90. doi: 10.1038/pcan.2013.57. Epub 2014 Jan 7. Prostate Cancer Prostatic Dis. 2014. PMID: 24394557 Free PMC article.
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, Thellenberg C, Jänes E, Enblad G, Ullen A, Hjälm-Eriksson M, Oldenburg J, Ost P, Lindberg J, Eklund M, Grönberg H. Crippa A, et al. Among authors: hjalm eriksson m. Trials. 2020 Jun 26;21(1):579. doi: 10.1186/s13063-020-04515-8. Trials. 2020. PMID: 32586393 Free PMC article.
18 results